Back to Search
Start Over
2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592
- Source :
- Immuno-Oncology and Technology. 16:100107
- Publication Year :
- 2022
- Publisher :
- Elsevier BV, 2022.
- Subjects :
- Oncology
Immunology and Allergy
Subjects
Details
- ISSN :
- 25900188
- Volume :
- 16
- Database :
- OpenAIRE
- Journal :
- Immuno-Oncology and Technology
- Accession number :
- edsair.doi...........c62c34305de548b46d43463c6e269682